Pancreatic cancer — Adjuvant therapy
Tóm tắt
Pancreatic cancer ranks tenth in terms of newly diagnosed cases, but just 10%–15% of these patients can undergo resection. Survival after curative surgery is dismal, as recurrences occur either locally or in the liver. Adjuvant treatment with either chemotherapy or chemoradiation (with or without maintenance chemotherapy) has been employed, to improve the poor prognosis. Justification for the use of chemoradiation, with follow on chemotherapy, is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. There has been no survival advantage demonstrated in the one randomized controlled trial that examined chemoradiation compared to chemotherapy. There is a clear cut survival advantage however with chemotherapy compared to observation, based on the results from two large randomized controlled trials, and supported by an individual patient data meta-analysis. The standard of care for adjuvant therapy based on level I evidence (from the ESPAC-1 trial) is post operative chemotherapy using 5-Fluorouracil with folinic acid providing a best estimate of 29% five years survival.
Tài liệu tham khảo
Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2006, 56: 106–130.
Ghaneh P, Sultana A, Shore S, et al. The case for adjuvant chemotherapy in pancreatic cancer. Best Pract Res Clin Gastroenterol, 2006, 20: 383–401.
Neoptolemos J, Russell RCG, Bramhall SR, et al. Low mortality following resection for pancreatic and periampullary tumors in 1026 patients. Brit J Surg, 1997, 84: 1370–1376.
Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control, 2006, 17: 403–409.
Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated with adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomised controlled trial. Ann Surg, 2001, 234: 758–768.
Abrams R, Lillemoe K, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet, 2001, 358: 1565.
Koshy M, Landry J, Cavanaugh S, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys, 2005, 61: 965–966.
Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg, 1997, 21: 195–200.
Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol, 2005, 23: 4532–4537.
Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater — results of a controlled, prospective, randomised multicentre study. Eur J Cancer, 1993, 29A: 698–703.
Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gall bladder carcinoma? A phase III multicentre prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 2002, 95: 1685–1695.
Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005, 92: 1372–1381.
Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 2001, 358: 1576–1585.
Neoptolemos JP, Stocken DD, Freiss H, et al. A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350: 1200–1210.
Bassi C, Stocken DD, Olah A, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg, 2005, 22: 353–363.
Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicentre, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. ASCO 2005, Orlando.
Kosuge T, Kiuchi T, Mukai K, et al. A multicenter randomised controlled trial to evaluate the effect of adjuvant cisplatin and 5-Fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol, 2006, 36: 159–165.
Ishikawa O, Ohigashi H, Imaoka S, et al. Regional chemotherapy to prevent hepatic metastases after resection of pancreatic cancer. Hepatogastroenterology, 1997, 44: 1541–1546.
Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg, 1994, 168: 361–364.
Ozaki H, Kinoshita T, Kosuge T, et al. Effectiveness of multimodality treatment for resectable pancreatic cancer. Int J Pancreatol, 1990, 7: 195–200.
Ozaki H, Kinoshita T, Kosuge T, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancreatol, 2000, 27: 217–224.
Link K, Formentini A, Gansauge F, et al. Regional coeliac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion, 1997, 58: 529–532.
Papachristou E, Link K, Schoenberg M. Regional coeliac artery infusion in the adjuvant treatment of pancreatic cancer. Anticancer Res, 2003, 23: 831–834.
Beger H, Gansauge F, Buchler M, et al. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastases. World J Surg, 1999, 23: 946–949.
Yamaue H, Tani M, Onishi H, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas, 2002, 25: 366–372.
Glanduik S. Ongoing clinical trials. Dig Surg, 2004, 21: 325–335.
Fossati V, Cattaneo GM, Zerbi A, et al. The role of intraoperative therapy by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas. Tumori, 1995, 81: 23–31.
Zerbi A, Fossati V, Parolini D. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer, 1994, 73: 2930–2935.
Hiraoka T, Uchino R, Kanemitsu K, et al. Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol, 1990, 7: 201–207.
Coquard R, Ayzac L, Gilly FN, et al. Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results. Radiother Oncol, 1997, 44: 271–275.
Reni M, Panucci MG, Ferreri AJ, et al. Effect of local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys, 2001, 50: 651–658.
Sindelar W, Kinsella T. Randomised trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Oncol Biol Phys, 1986, 12(Suppl 1): 148.
Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg, 1999, 230: 776–784.
Smeenk H, van Eijck C, Khe T, et al. Long-term survival and metastatic pattern of pancreatic cancer after adjuvant chemoradiation or observation; long-term results of EORTC-trial 40891. HPB, 2006, 8(Suppl 2): Abstract PL1.4:3.
Garofalo M, Flannery T, Regine W. The case for adjuvant chemoradiation for pancreatic cancer. Best Pract Res Clin Gastroenterol, 2006, 20: 403–416.
Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol, 2006, 58: 231–241.
Kalser M, Ellenberg S. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg, 1985, 120: 899–903.
Doughlass H. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer, 1987, 59: 2006–2010.
Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation 5FU vs. gemcitabine for resected pancreatic adenocarcinoma. J Clin Oncol, 2005, 24: Abstract no. 4007.
Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma — CapRI: study protocol [ISRCTN62866759]. BMC Cancer, 2005, 5: 37.
Picozzi V, Kozarek R, Traverso L. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg, 2003, 185: 476–480.